Hong Jian

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 253 citations · Full text

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Oncology · 2022 · 227 citations

Oncology, First Interim Results, Bevacizumab Biosimilar Ibi305 +10

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 181 citations

Oncology, Disease Progression, Second Interim Analysis +9

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang et al. · Journal of Thoracic Oncology · 2020 · 149 citations · Full text

Pretreated Patients, Novel Therapy, Medicine +8

Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial

Yi Jiang, Lingshuang Liu, Liping Shen et al. · Complementary Therapies in Medicine · 2015 · 96 citations

Traditional Chinese Medicine, Medicine, Maintenance Therapy +5